prikaz prve stranice dokumenta Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Access restricted to students and staff of home institution
Scientific paper - Case study
Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Anti-Cancer Drugs, 29 (2018), 3; 281-285. https://doi.org/10.1097/CAD.0000000000000587
Drpa, Gordana; Sreter, Katherina B.; Manojlovic, Spomenka; Kukulj, Suzana

Cite this document

Drpa, G., Sreter, K. B., Manojlovic, S. & Kukulj, S. (2018). Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?. Anti-Cancer Drugs, 29. (3), 281-285. doi: 10.1097/CAD.0000000000000587

Drpa, Gordana, et al. "Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?." Anti-Cancer Drugs, vol. 29, no. 3, 2018, pp. 281-285. https://doi.org/10.1097/CAD.0000000000000587

Drpa, Gordana, Katherina B. Sreter, Spomenka Manojlovic and Suzana Kukulj. "Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?." Anti-Cancer Drugs 29, no. 3 (2018): 281-285. https://doi.org/10.1097/CAD.0000000000000587

Drpa, G., et al. (2018) 'Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?', Anti-Cancer Drugs, 29(3), pp. 281-285. doi: 10.1097/CAD.0000000000000587

Drpa G, Sreter KB, Manojlovic S, Kukulj S. Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?. Anti-Cancer Drugs [Internet]. 2018 March [cited 2024 November 20];29(3):281-285. doi: 10.1097/CAD.0000000000000587

G. Drpa, K. B. Sreter, S. Manojlovic and S. Kukulj, "Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?", Anti-Cancer Drugs, vol. 29, no. 3, pp. 281-285, March 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:381374. [Accessed: 20 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
AuthorGordana Drpa
AuthorKatherina B. Sreter
AuthorSpomenka Manojlovic
AuthorSuzana Kukulj
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Adenocarcinoma (AC) is the most common type of primary pulmonary malignancy. Lung carcinoid, however, is a rare neuroendocrine tumor. Their coexistence is extremely uncommon. We report the unique case of synchronous advanced lung AC of the right upper lobe (stage IIIB) and typical endobronchial carcinoid tumor in the contralateral lower lobe in a 49-year-old white female who had never smoked. PET-computed tomography scan revealed a fluorine-18-fluorodeoxyglucose-avid AC lesion, whereas the carcinoid tumor was fluorine-18-fluorodeoxyglucose occult. After two lines of platinum-based combination chemotherapies and radiotherapy, the AC progressed, and oral tyrosine kinase inhibitor therapy with erlotinib was initiated in third line. On erlotinib, the AC remained stable for 50 months until disease progression, whereas the carcinoid completely regressed. Molecular testing of the rebronchoscopied AC revealed an exon 19 deletion mutation in the epidermal growth factor receptor (EGFR) gene, whereas the carcinoid was retrospectively EGFR mutation negative. The patient eventually succumbed to ileus caused by intra-abdominal spread of disease, surviving a remarkable 80 months with good performance status throughout most of the follow-up period. To the best of our knowledge, this is the first reported case of synchronous primary lung cancers with different EGFR mutation status, describing an unexpected response of an EGFR-wild-type carcinoid to third-line erlotinib.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleAnti-Cancer Drugs
Numberingvol. 29, no. 3, pp. 281-285
p-ISSN0959-4973
DOIhttps://doi.org/10.1097/CAD.0000000000000587
URN:NBNurn:nbn:hr:220:381374
Publication2018-03
Document URLhttps://journals.lww.com/00001813-201803000-00010
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2024-09-20 10:21:23